NCT03856099

A Multicenter, Open-Label, Phase Ⅱ Clinical Trial to Evaluate the Safety and Efficacy of TTAC-0001, a Fully Human Monoclonal Antibody in Patients with Recurrent Glioblastoma Progressed on Bevacizumab Including Therapy

  • Enrollment

    This study is not currently enrolling.

  • Associated Conditions

  • Research Area

    Cancer Research

  • Principal Investigator

    Herbert Newton

  • Sponsor

    PharmAbcine

The aim of this study is to assess the safety and effectiveness of the study drug, TTAC-0001 to patients with recurrent glioblastoma which has progressed on bevacizumab treatment. Another aim is to measure the levels of TTAC-0001 in the blood over time (called pharmacokinetic or PK testing). The study will also assess changes in the level of tumor biomarkers in the blood over time (called pharmacodynamic or PD testing).